<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
      <PMID Version="1">35468515</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1768-3254</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>237</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>European journal of medicinal chemistry</Title>
          <ISOAbbreviation>Eur J Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Design, synthesis and antibacterial activity of novel pleuromutilin derivatives with thieno[2,3-d]pyrimidine substitution.</ArticleTitle>
        <Pagination>
          <StartPage>114398</StartPage>
          <MedlinePgn>114398</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2022.114398</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0223-5234(22)00300-2</ELocationID>
        <Abstract>
          <AbstractText>A series of novel pleuromutilin derivatives with substituted thienopyrimidines were designed, synthesized, and evaluated for antibacterial act ivity. In this study, the activities of these compounds were investigated using the inhibition circle test, the minimum inhibitory concentration (MIC) test, real-time growth curves, time-kill kinetic assays, cytotoxicity assays, and molecular docking. Most of the tested compounds exhibited moderate antibacterial activity against Staphylococcus aureus, Streptococcus agalactiae, and Escherichia coli. Compound A11 was the most active and displayed bacteriostatic activities against methicillin-resistant S. aureus, with MIC values as low as 0.00191 μg/mL, which is 162 and 32 times lower than that of the marketed antibiotics tiamulin and retapamulin, respectively. Furthermore, the mechanism of action of A11 was confirmed by molecular docking studies.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ding</LastName>
            <ForeName>Rongcai</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Weifang Medical University, No.7166 Baotong Road, Weifang, 261053, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xiaoxia</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Weifang Medical University, No.7166 Baotong Road, Weifang, 261053, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fu</LastName>
            <ForeName>Jianfang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Weifang Medical University, No.7166 Baotong Road, Weifang, 261053, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Yaoyao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Weifang Medical University, No.7166 Baotong Road, Weifang, 261053, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yingxue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Weifang Medical University, No.7166 Baotong Road, Weifang, 261053, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yajing</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Weifang Medical University, No.7166 Baotong Road, Weifang, 261053, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Jinlong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Weifang Medical University, No.7166 Baotong Road, Weifang, 261053, PR China. Electronic address: majinlong99@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Jinxing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Weifang Medical University, No.7166 Baotong Road, Weifang, 261053, PR China. Electronic address: jinxinghu2013@wfmc.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Eur J Med Chem</MedlineTA>
        <NlmUniqueID>0420510</NlmUniqueID>
        <ISSNLinking>0223-5234</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antibacterial activity</Keyword>
        <Keyword MajorTopicYN="N">Pleuromutilin derivatives</Keyword>
        <Keyword MajorTopicYN="N">Thienopyrimidine</Keyword>
        <Keyword MajorTopicYN="N">Time-kill curves</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>20</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35468515</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ejmech.2022.114398</ArticleId>
        <ArticleId IdType="pii">S0223-5234(22)00300-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
